Universität zu Köln

Journal Article

Agathangelidis, Andreas ORCID: 0000-0002-8467-7945, Chatzidimitriou, Anastasia, Gemenetzi, Katerina, Giudicelli, Veronique, Karypidou, Maria, Plevova, Karla ORCID: 0000-0002-6148-8877, Davis, Zadie, Yan, Xiao-Jie, Jeromin, Sabine, Schneider, Christof, Pedersen, Lone Bredo, Tschumper, Renee C., Sutton, Lesley-Ann, Baliakas, Panagiotis, Scarfo, Lydia, van Gastel, Ellen J., Armand, Marine, Tausch, Eugen, Biderman, Bella, Baer, Constance, Bagnara, Davide, Navarro, Alba, de Septenville, Anne Langlois, Guido, Valentina, Mitterbauer-Hohendanner, Gerlinde, Dimovski, Aleksandar, Brieghel, Christian ORCID: 0000-0002-1816-8106, Lawless, Sarah, Meggendorfer, Manja, Brazdilova, Kamila, Ritgen, Matthias, Facco, Monica, Tresoldi, Cristina, Visentin, Andrea ORCID: 0000-0003-0271-7200, Patriarca, Andrea ORCID: 0000-0003-4415-2906, Catherwood, Mark, Bonello, Lisa, Sudarikov, Andrey ORCID: 0000-0001-9463-9187, Vanura, Katrina, Roumelioti, Maria, Francova, Hana Skuhrova, Moysiadis, Theodoros ORCID: 0000-0003-1673-196X, Veronese, Silvio, Giannopoulos, Krzysztof, Mansouri, Larry, Karan-Djurasevic, Teodora, Sandaltzopoulos, Raphael, Bodor, Csaba, Fais, Franco ORCID: 0000-0002-6643-7083, Kater, Arnon, Panovska, Irina, Rossi, Davide, Alshemmari, Salem ORCID: 0000-0002-5597-5839, Panagiotidis, Panagiotis, Costeas, Paul, Espinet, Blanca ORCID: 0000-0002-4294-8145, Antic, Darko, Foroni, Letizia, Montillo, Marco, Trentin, Livio, Stavroyianni, Niki, Gaidano, Gianluca ORCID: 0000-0002-4681-0151, di Celle, Paola Francia, Niemann, Carsten ORCID: 0000-0001-9880-5242, Campo, Elias, Anagnostopoulos, Achilles, Pott, Christiane, Fischer, Kirsten, Hallek, Michael, Oscier, David, Stilgenbauer, Stephan, Haferlach, Claudia, Jelinek, Diane, Chiorazzi, Nicholas, Pospisilova, Sarka, Lefranc, Marie-Paule, Kossida, Sofia, Langerak, Anton W., Belessi, Chrysoula, Davi, Frederic, Rosenquist, Richard, Ghia, Paolo and Stamatopoulos, Kostas ORCID: 0000-0001-8529-640X (2021). Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood, 137 (10). S. 1365 - 1377. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Al-Sawaf, Othman, Fischer, Kirsten, Herling, Carmen D., Ritgen, Matthias, Boettcher, Sebastian, Bahlo, Jasmin, Elter, Thomas, Stilgenbauer, Stephan, Eichhorst, Barbara F., Busch, Raymonde, Elberskirch, Ute, Abenhardt, Wolfgang, Kneba, Michael, Hallek, Michael and Wendtner, Clemens-Martin (2017). Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. Eur. J. Haematol., 98 (3). S. 254 - 263. HOBOKEN: WILEY. ISSN 1600-0609

Al-Sawaf, Othman, Lilienweiss, Esther, Bahlo, Jasmin, Robrecht, Sandra, Fink, Anna-Maria, Patz, Michaela, Tandon, Maneesh, Jiang, Yanwen, Schary, William, Ritgen, Matthias, Tausch, Eugen, Stilgenbauer, Stephan, Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael and Kreuzer, Karl-Anton (2020). High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood, 135 (11). S. 866 - 871. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Al-Sawaf, Othman, Zhang, Can, Lu, Tong, Liao, Michael Z., Panchal, Anesh, Robrecht, Sandra, Ching, Travers ORCID: 0000-0002-5577-3516, Tandon, Maneesh, Fink, Anna-Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Boettcher, Sebastian, Kreuzer, Karl-Anton, Chyla, Brenda, Miles, Dale, Wendtner, Clemens-Martin, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael and Fischer, Kirsten (2021). Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. J. Clin. Oncol., 39 (36). S. 4049 - 4062. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Al-Sawaf, Othman, Zhang, Can, Tandon, Maneesh, Sinha, Arijit, Fink, Anna Maria, Robrecht, Sandra, Tausch, Eugen, Schary, William L., Ritgen, Matthias, Wendtner, Clemens Martin, Kreuzer, Karl A., Eichhorst, Barbara, Stilgenbauer, Stephan, Hallek, Michael J. and Fischer, Kirsten (2020). Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. J. Clin. Oncol., 38 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Al-Sawaf, Othman, Zhang, Can, Tandon, Maneesh, Sinha, Arijit, Fink, Anna-Maria, Robrecht, Sandra, Samoylova, Olga, Liberati, Anna M., Pinilla-Ibarz, Javier, Opat, Stephen, Sivcheva, Liliya, Le Du, Katell, Fogliatto, Laura M., Niemann, Carsten U., Weinkove, Robert, Robinson, Sue, Kipps, Thomas J., Tausch, Eugen, Schary, William, Ritgen, Matthias, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Eichhorst, Barbara, Stilgenbauer, Stephan, Hallek, Michael and Fischer, Kirsten (2020). Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol., 21 (9). S. 1188 - 1201. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Boeitcher, Sebastian, Ritgen, Matthias, Fischer, Kirsten, Stilgenbauer, Stephan, Busch, Raymonde, Fingerle-Rowson, Gunter R., Fink, Anna-Maria, Buehler, Andreas, Winkler, Dirk, Wenger, Michael K., Mendila, Myriam, Wendtner, Clemens, Eichhorst, Barbara, Doehner, Hartmut, Hallek, Michael and Kneba, Michael (2011). Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups-Results From the CLL8 Trial of the German CLL Study Group (GCLLSG). Blood, 118 (21). S. 775 - 776. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Cramer, Paula ORCID: 0000-0003-4046-9922, Furstenau, Moritz, Robrecht, Sandra, Giza, Adam, Zhang, Can, Fink, Anna-Maria, Fischer, Kirsten, Langerbeins, Petra, Al-Sawaf, Othman, Tausch, Eugen, Schneider, Christof, Schetelig, Johannes, Dreger, Peter, Bottcher, Sebastian, Kreuzer, Karl-Anton, Schilhabel, Anke, Ritgen, Matthias, Bruggemann, Monika, Kneba, Michael, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2022). Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG) a multicentre, open-label, phase 2 trial. Lancet Haematol., 9 (10). S. E745 - 11. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Al-Sawaf, Othman, Engelke, Anja, Fink, Anna-Maria, Fischer, Kirsten, Tausch, Eugen, Seiler, Till, von Weikersthal, Ludwig Fischer, Hebart, Holger, Kreuzer, Karl-Anton, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2018). Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol., 19 (9). S. 1215 - 1229. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Cramer, Paula, von Tresckow, Julia, Robrecht, Sandra, Bahlo, Jasmin, Furstenau, Moritz ORCID: 0000-0002-6593-0140, Langerbeins, Petra, Pflug, Natali, Al-Sawaf, Othman ORCID: 0000-0001-9895-0570, Heinz, Werner J., Vehling-Kaiser, Ursula, Durig, Jan, Tausch, Eugen, Hensel, Manfred, Sasse, Stephanie, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl-Anton, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2021). Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO). Haematologica, 106 (2). S. 543 - 555. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Dimier, Natalie, Delmar, Paul, Ward, Carol, Morariu-Zamfir, Rodica, Fingerle-Rowson, Guenter, Bahlo, Jasmin, Fischer, Kirsten, Eichhorst, Barbara, Goede, Valentin, van Dongen, Jacques J. M., Ritgen, Matthias, Boettcher, Sebastian, Langerak, Anton W., Kneba, Michael and Hallek, Michael (2018). A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood, 131 (9). S. 955 - 963. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Dimier, Natalie, Delmar, Paul, Ward, Carol, Morariu-Zamfir, Rodica, Fingerle-Rowson, Gunter, Bahlo, Jasmin, Fischer, Kirsten, Eichhorst, Barbara F., Goede, Valentin, van Dongen, Jacques J. M., Ritgen, Matthias, Boettcher, Sebastian, Langerak, Anton W., Kneba, Michael and Hallek, Michael (2015). A Model for Predicting Effect of Treatment on Progression-Free Survival Using Minimal Residual Disease As a Surrogate Endpoint in Chronic Lymphocytic Leukemia. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Dreger, Peter, Doehner, Hartmut, Ritgen, Matthias, Boettcher, Sebastian, Busch, Raymonde, Dietrich, Sascha ORCID: 0000-0002-0648-1832, Bunjes, Donald, Cohen, Sandra, Schubert, Joerg, Hegenbart, Ute, Beelen, Dietrich ORCID: 0000-0001-5050-220X, Zeis, Matthias, Stadler, Michael, Hasenkamp, Justin, Uharek, Lutz, Scheid, Christof, Humpe, Andreas, Zenz, Thorsten, Winkler, Dirk, Hallek, Michael, Kneba, Michael, Schmitz, Norbert and Stilgenbauer, Stephan (2010). Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood, 116 (14). S. 2438 - 2448. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Estenfelder, Sven, Tausch, Eugen, Robrecht, Sandra, Bahlo, Jasmin, Goede, Valentin, Ritgen, Matthias, van Dongen, Jacques J. M., Langerak, Anton W., Fingerle-Rowson, Gunter, Kneba, Michael, Fischer, Kirsten, Hallek, Michael, Dohner, Hartmut and Stilgenbauer, Stephan (2016). Gene Mutations and Treatment Outcome in the Context of Chlorambucil (Clb) without or with the Addition of Rituximab (R) or Obinutuzumab (GA-101, G) - Results of an Extensive Analysis of the Phase III Study CLL11 of the German CLL Study Group. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fink, Anna, Busch, Raymonde, Pflug, Natali, Boettcher, Sebastian, Winkler, Dirk, Buehler, Andreas, Ritgen, Matthias, Fischer, Kirsten, Eichhorst, Barbara, Wendtner, Clemens-Martin, Mendila, Myriam, Wenger, Michael K., Doehner, Hartmut, Kneba, Michael, Stilgenbauer, Stephan and Hallek, Michael (2011). Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG). Blood, 118 (21). S. 446 - 448. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Fink, Anna Maria, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Aldaoud, Ali, Hebart, Holger, Jentsch-Ullrich, Kathleen, Doerfel, Steffen, Fischer, Kirsten, Wendtner, Clemens-Martin, Noesslinger, Thomas, Ghia, Paolo ORCID: 0000-0003-3750-7342, Bosch, Francesc ORCID: 0000-0001-9241-2886, Kater, Arnon P., Dohner, Hartmut, Kneba, Michael, Kreuzer, Karl-Anton, Tausch, Eugen, Stilgenbauer, Stephan, Ritgen, Matthias, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2017). Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol., 4 (10). S. E475 - 12. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Fischer, Kirsten, Al-Sawaf, Othman, Fink, Anna-Maria, Dixon, Mark, Bahlo, Jasmin, Warburton, Simon, Kipps, Thomas J., Weinkove, Robert ORCID: 0000-0003-3645-7988, Robinson, Sue, Dreyling, Martin H., Opat, Stephen, Owen, Carolyn J., Lopez, Javier, Humphrey, Kathryn, Humerickhouse, Rod A., Tausch, Eugen, Eichhorst, Barbara, Wendtner, Clemens-M., Langerak, Anton W., van Dongen, Jacques J. M., Ritgen, Matthias, Boettcher, Sebastian, Stilgenbauer, Stephan, Goede, Valentin, Mobasher, Mehrdad and Hallek, Michael (2016). Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fischer, Kirsten, Al-Sawaf, Othman, Fink, Anna-Maria, Dixon, Mark, Bahlo, Jasmin, Warburton, Simon, Kipps, Thomas J., Weinkove, Robert ORCID: 0000-0003-3645-7988, Robinson, Sue, Seiler, Till, Opat, Stephen, Owen, Carolyn, Lopez, Javier, Humphrey, Kathryn, Humerickhouse, Rod, Tausch, Eugen, Frenzel, Lukas, Eichhorst, Barbara, Wendtner, Clemens-M., Stilgenbauer, Stephan, Langerak, Anton W., van Dongen, Jacque J. M., Boettcher, Sebastian, Ritgen, Matthias, Goede, Valentin, Mobasher, Mehrdad and Hallek, Michael (2017). Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood, 129 (19). S. 2702 - 2706. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fischer, Kirsten, Cramer, Paula, Busch, Raymonde, Boettcher, Sebastian, Bahlo, Jasmin, Schubert, Joeerg, Pflueger, Karl H., Schott, Silke, Goede, Valentin, Isfort, Susanne, von Tresckow, Julia, Fink, Anna-Maria, Buehler, Andreas, Winkler, Dirk, Kreuzer, Karl-Anton, Staib, Peter, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Eichhorst, Barbara F., Hallek, Michael, Stilgenbauer, Stephan and Wendtner, Clemens-Martin (2012). Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol., 30 (26). S. 3209 - 3217. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Fischer, Kirsten, Fink, Anna-Maria, Bishop, Helen, Dixon, Mark, Bahlo, Jasmin, Chol, Michael Y., Weinkove, Robert ORCID: 0000-0003-3645-7988, Robinson, Sue, Dreyling, Martin, Seiler, Till, Opat, Stephen, Owen, Carolyn, Lopez, Javier, Sr., Kutsch, Nadine, Tausch, Eugen, Ritgen, Matthias, Humerickhouse, Rod A., Humphrey, Kathryn, Wenger, Michael K., Goede, Valentin, Eichhorst, Barbara, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Kipps, Thomas J. and Hallek, Michael (2015). Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase Ill Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fuerstenau, Moritz, Fink, Anna Maria, Schilhabel, Anke, Weiss, Jonathan, Robrecht, Sandra, Eckert, Robert, de la Serna, Javier, Crespo, Marta ORCID: 0000-0002-7732-7808, Coscia, Marta, Vitale, Candida, Boettcher, Sebastian, Weppner, Gesche, Ritgen, Matthias, Stilgenbauer, Stephan, Tausch, Eugen, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara, Brueggemann, Monika and Herling, Carmen D. (2021). B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood, 137 (16). S. 2267 - 2272. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fuerstenau, Moritz, Fink, Anna-Maria, Herling, Carmen, Maurer, Christian, Kutsch, Nadine, De La Serna, Javier, Coscia, Marta, Crespo, Marta, Bosch, Francesc ORCID: 0000-0001-9241-2886, Noesslinger, Thomas, Ghia, Paolo, Kater, Arnon P., Ritgen, Matthias, Schilhabel, Anke, Stilgenbauer, Stephan, Tausch, Eugen, Fischer, Kirsten, Hallek, Michael J. and Eichhorst, Barbara (2018). B-cell acute lymphoblastic leukemia (BALL) in CLL patients treated with lenalidomide. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Furstenau, Moritz, Bahlo, Jasmin, Fink, Anna-Maria, Lange, Elisabeth, Dreger, Peter, Dreyling, Martin, Hess, Georg, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, Boettcher, Sebastian, Hallek, Michael and Eichhorst, Barbara (2018). Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Furstenau, Moritz, Thus, Yvonne, Robrecht, Sandra, Mellink, Clemens, Van der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie M. N., Von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjorn, Illmer, Thomas, Schoettker, Bjorn, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Noesslinger, Thomas, Regelink, Josien, Dompeling, Ellen C., Lindstroem, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen Simon, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brueggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Eldering, Eric, Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton and Kater, Arnon P. (2022). High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Furstenau, Moritz ORCID: 0000-0002-6593-0140, Weiss, Jonathan, Giza, Adam, Franzen, Fabian, Robrecht, Sandra, Fink, Anna-Maria, Fischer, Kirsten, Schneider, Christof, Tausch, Eugen, Stilgenbauer, Stephan, Ritgen, Matthias, Schilhabel, Anke, Brueggemann, Monika, Eichhorst, Barbara, Hallek, Michael and Cramer, Paula ORCID: 0000-0003-4046-9922 (2022). Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax. Clin. Cancer Res., 28 (19). S. 4203 - 4212. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1557-3265

Goede, Valentin, Engelke, Anja, Fischer, Kirsten, Lopez Jimenez, Javier, Kuzmin, Alexej, Dyer, Martin J. S., Le Du, Katell, Liberati, Anna Marina, Schlag, Rudolf, Langerak, Anton W., Ritgen, Matthias, Stilgenbauer, Stephan, Asikanius, Elina, Humphrey, Kathryn, Wenger, Michael K., Fingerle-Rowson, Guenter and Hallek, Michael (2014). Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Goede, Valentin, Fischer, Kirsten, Busch, Raymonde, Engelke, Anja, Eichhorst, Barbara, Wendtner, Clemens M., Chagorova, Tatiana, de la Serna, Javier, Dilhuydy, Marie-Sarah, Illmer, Thomas, Opat, Stephen, Owen, Carolyn J., Samoylova, Olga, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Doehner, Hartmut, Langerak, Anton W., Ritgen, Matthias, Kneba, Michael, Asikanius, Elina, Humphrey, Kathryn, Wenger, Michael and Hallek, Michael (2014). Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. N. Engl. J. Med., 370 (12). S. 1101 - 1111. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Huber, Henriette, Edenhofer, Simone, von Tresckow, Julia, Robrecht, Sandra, Zhang, Can, Tausch, Eugen, Schneider, Christof, Bloehdorn, Johannes ORCID: 0000-0003-1433-9702, Fuerstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna L., Duerig, Jan, Boettcher, Sebastian, Niemann, Carsten U., Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Doehner, Hartmut, Hallek, Michael ORCID: 0000-0002-7425-4455, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia. Blood, 139 (9). S. 1318 - 1330. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Huber, Henriette, Tausch, Eugen, Schneider, Christof, Edenhofer, Simone, Von Tresckow, Julia, Robrecht, Sandra, Giza, Adam, Zhang, Can, Furstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna Lena, Duerig, Jan, Boettcher, Sebastian, Niemann, Carsten Utoft, Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Doehner, Hartmut, Hallek, Michael, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Julia, Von Tresckow, Carsten, Niemann, Kater, Arnon P., Bahlo, Jasmin, Farstenau, Moritz, Fink, Anna-Maria, Gregor, Michael, Thornton, Patrick, Tadmor, Tamar, Fischer, Kirsten, Ritgen, Matthias, Kreuzer, Karl A., Eldering, Eric, Stilgenbauer, Stephan, Van Oers, Marinus, Geisler, Christian, Hallek, Michael J. and Eichhorst, Barbara (2018). The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL). J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Julia, Von Tresckow, Cramer, Paula, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Langerbeins, Petra, Fuerstenau, Moritz, Engelke, Anja, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl A., Ritgen, Matthias, Boettcher, Sebastian, Wendtner, Clemens Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael J. (2018). Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kovacs, Gabor, Boettcher, Sebastian, Bahlo, Jasmin, Kluth, Sandra, Ritgen, Matthias, Fink, Anna Maria, Stodden, Irene, Cramer, Paula, von Tresckow, Julia, Maurer, Christian, Doehner, Hartmut, Stilgenbauer, Stephan, Kneba, Michael, Fischer, Kirsten, Hallek, Michael and Eichhorst, Barbara (2014). Value of Minimal Residual Disease (MRD) Negative Status at Response Evaluation in Chronic Lymphocytic Leukemia (CLL): Combined Analysis of Two Phase III Studies of the German CLL Study Group (GCLLSG). Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kovacs, Gabor, Robrecht, Sandra, Fink, Anna Maria, Bahlo, Jasmin, Cramer, Paula, von Tresckow, Julia, Maurer, Christian, Langerbeins, Petra, Fingerle-Rowson, Gunter, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Stilgenbauer, Stephan, Klapper, Wolfram, Wendtner, Clemens-Martin, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara and Boettcher, Sebastian (2016). Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. J. Clin. Oncol., 34 (31). S. 3758 - 3775. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kramer, Isabelle, Stilgenbauer, Stephan, Dietrich, Sascha, Bottcher, Sebastian, Ritgen, Matthias, Bunjes, Donald, Zeis, Matthias, Stadler, Michael, Bittenbring, Joerg Thomas, Hegenbart, Ute, Hallek, Michael, Kneba, Michael, Schmitz, Norbert, Dohner, Hartmut and Dreger, Peter (2016). Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kutsch, Nadine, Holmes, Emily Eva, Robrecht, Sandra, Schueler, Gudrun, Vehling-Kaiser, Ursula, Decker, Thomas, Mueller-Hagen, Sigrun, Heinisch, Karin, Boettcher, Sebastian, Ritgen, Matthias, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Fink, Anna Maria, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Wendtner, Clemens-Martin (2023). Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients. Leuk. Lymphoma, 64 (2). S. 478 - 483. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Kutsch, Nadine, Pallasch, Christian, Decker, Thomas ORCID: 0000-0003-3814-8775, Hebart, Holger, Chow, Kai Uwe, Graeven, Ullrich, Kisro, Jens, Kroeber, Alexander, Tausch, Eugen, Fischer, Kirsten, Fink, Anna-Maria, Wendtner, Clemens-Martin, Ritgen, Matthias, Stilgenbauer, Stephan, Zhang, Danjie, Li, Biao, Jurgensmeier, Juliane M., Rajakumaraswamy, Nishanthan, Bhargava, Pankaj, Hallek, Michael ORCID: 0000-0002-7425-4455 and Eichhorst, Barbara (2022). Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. Hemasphere, 6 (6). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Kutsch, Nadine, Pallasch, Christian, Tausch, Eugen, Boehme, Volkmar, Ritgen, Matthias, Liersch, Ruediger, Wacker, Alexander, Jacobs, Georg, Trappe, Ralf Ulrich ORCID: 0000-0001-7565-7160, Dreger, Peter, Fischer, Kirsten, Fink, Anna-Maria, Stilgenbauer, Stephan, Zhai, Shuyan, Li, Biao, Jurgensmeier, Juliane M., Rajakumaraswamy, Nishanthan, Bhargava, Pankaj, Hallek, Michael ORCID: 0000-0002-7425-4455 and Eichhorst, Barbara F. (2022). Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. Hemasphere, 6 (4). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Landau, Dan A., Tausch, Eugen, Boettcher, Sebastian, Stewart, Chip, Bozic, Ivana, Leischner, Iganty, Rosebrock, Daniel, Taylor-Weiner, Amaro, Mertens, Daniel, Sougnez, Carrie, Kless, Sabrina, Kneba, Michael, Ritgen, Matthias, Kluth, Sandra, Bahlo, Jasmin, Fink, Anna-Maria, Fischer, Kirsten, Gabriel, Stacey, Lander, Eric, Dohner, Hartmut ORCID: 0000-0003-2116-5536, Hallek, Michael, Neuberg, Donna S., Nowak, Martin, Getz, Gad, Stilgenbauer, Stephan and Wu, Catherine J. (2015). Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Landau, Dan A., Tausch, Eugen, Taylor-Weiner, Amaro N., Bottcher, Sebastian, Bahlo, Jasmin, Stewart, Chip, Edelmann, Jennifer, Kluth, Sandra, Mertens, Daniel, Kneba, Michael, Kless, Sabrina, Sougnez, Carrie, Fischer, Kirsten, Ritgen, Matthias, Gabriel, Stacey, Lander, Eric, Dohner, Hartmut ORCID: 0000-0003-2116-5536, Hallek, Michael, Getz, Gad, Neuberg, Donna, Stilgenbauer, Stephan and Wu, Catherine J. (2014). Subclonal Driver Mutations Predict Shorter Progression Free Survival in Chronic Lymphocytic Leukemia Following First-Line Chemo(immuno) Therapy: Results from the CLL8 Trial. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Landau, Dan A., Tausch, Eugen, Taylor-Weiner, Amaro N., Stewart, Chip, Reiter, Johannes G. ORCID: 0000-0002-0170-7353, Bahlo, Jasmin, Kluth, Sandra, Bozic, Ivana ORCID: 0000-0003-2761-825X, Lawrence, Mike, Boettcher, Sebastian, Carter, Scott L., Cibulskis, Kristian, Mertens, Daniel ORCID: 0000-0003-0227-7188, Sougnez, Carrie L., Rosenberg, Mara ORCID: 0000-0001-6400-3161, Hess, Julian M., Edelmann, Jennifer, Kless, Sabrina, Kneba, Michael, Ritgen, Matthias, Fink, Anna, Fischer, Kirsten, Gabriel, Stacey, Lander, Eric S., Nowak, Martin A., Doehner, Hartmut, Hallek, Michael, Neuberg, Donna, Getz, Gad, Stilgenbauer, Stephan and Wu, Catherine J. (2015). Mutations driving CLL and their evolution in progression and relapse. Nature, 526 (7574). S. 525 - 542. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-4687

Langerak, Anton W., Ritgen, Matthias, Goede, Valentin, Robrecht, Sandra, Bahlo, Jasmin, Fischer, Kirsten, Steurer, Michael, Trneny, Marek, Mulligan, Stephen P., Mey, Ulrich J. M., Trunzer, Kerstin, Fingerle-Rowson, Guenter, Humphrey, Kathryn, Stilgenbauer, Stephan, Boettcher, Sebastian, Brueggemann, Monika, Hallek, Michael, Kneba, Michael and van Dongen, Jacques J. M. (2019). Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood, 133 (5). S. 494 - 498. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Pflug, Natali, Chakupurakal, Geothy, Fink, Anna-Maria, Robrecht, Sandra, Herling, Marco, Cramer, Paula, Holtick, Udo, Theurich, Sebastian ORCID: 0000-0001-5706-8258, Schetelig, Johannes, Fischer, Kirsten, Ritgen, Matthias, Scheid, Christof, Eichhorst, Barbara, Dreger, Peter, Hallek, Michael and von Bergwelt-Baildon, Michael (2021). Obinutuzumab in Allogeneic Transplantation for CLL and Richter's Transformation in the Age of Targeted Therapies. Hemasphere, 5 (12). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Scheffold, Annika, Jebaraj, Billy Michael Chelliah, Jaramillo, Sonia, Tausch, Eugen, Steinbrecher, Daniela, Hahn, Michael, Boettcher, Sebastian, Ritgen, Matthias, Bunjes, Donald, Zeis, Matthias, Stadler, Michael, Uharek, Lutz, Scheid, Christoph, Hegenbart, Ute, Hallek, Michael, Kneba, Michael, Schmitz, Norbert, Doehner, Hartmut, Dreger, Peter and Stilgenbauer, Stephan (2017). Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial. Br. J. Haematol., 179 (2). S. 342 - 347. HOBOKEN: WILEY. ISSN 1365-2141

Scheffold, Annika, Jebaraj, Billy Michael Chelliah, Tausch, Eugen, Boettcher, Sebastian, Ritgen, Matthias, Bunjes, Donald, Zeis, Matthias, Stadler, Michael, Uharek, Lutz, Scheid, Christof, Hegenbart, Ute, Hallek, Michael, Kneba, Michael, Schmitz, Norbert, Doehner, Hartmut, Dreger, Peter and Stilgenbauer, Stephan (2014). Telomere Lenght and Outcome of Allogeneic Stem Cell Transplantation for Poor Risk Chronic Lymphocytic Leukemia: Results from the GCLLSG CLL3X Trial. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Schilhabel, Anke, Walter, Peter Jonas, Cramer, Paula ORCID: 0000-0003-4046-9922, von Tresckow, Julia, Kohlscheen, Saskia, Szczepanowski, Monika ORCID: 0000-0001-5482-8880, Laqua, Anna, Fischer, Kirsten, Eichhorst, Barbara, Boettcher, Sebastian, Schneider, Christof, Tausch, Eugen, Brueggemann, Monika, Kneba, Michael, Hallek, Michael ORCID: 0000-0002-7425-4455 and Ritgen, Matthias (2022). CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis. Cancers, 14 (19). BASEL: MDPI. ISSN 2072-6694

Stilgenbauer, Stephan, Busch, Raymonde, Schnaiter, Andrea, Paschka, Peter, Rossi, Marianna, Doehner, Konstanze, Zenz, Thorsten, Buehler, Andreas, Winkler, Dirk, Edelmann, Jennifer, Mertens, Daniel, Bullinger, Lars, Kless, Sabrina, Mack, Silja, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Jaeger, Ulrich, Lichter, Peter, Patten, Nancy, Wenger, Michael K., Mendila, Myriam, Fingerle-Rowson, Gunter, Cazzola, Mario, Wendtner, Clemens, Fink, Anna Maria, Fischer, Kirsten, Hallek, Michael and Doehner, Hartmut (2012). Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial. Blood, 120 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Stilgenbauer, Stephan, Schnaiter, Andrea, Paschka, Peter, Zenz, Thorsten, Rossi, Marianna ORCID: 0000-0003-1661-1511, Doehner, Konstanze, Buehler, Andreas, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Winkler, Dirk, Tausch, Eugen, Hoth, Patrick, Edelmann, Jennifer, Mertens, Daniel ORCID: 0000-0003-0227-7188, Bullinger, Lars, Bergmann, Manuela, Kless, Sabrina, Mack, Silja, Jaeger, Ulrich, Patten, Nancy, Wu, Lin, Wenger, Michael K., Fingerle-Rowson, Guenter, Lichter, Peter, Cazzola, Mario, Wendtner, Clemens M., Fink, Anna M., Fischer, Kirsten, Busch, Raymonde, Hallek, Michael and Doehner, Hartmut (2014). Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood, 123 (21). S. 3247 - 3255. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Tausch, Eugen, Schneider, Christof, Furstenau, Moritz, Robrecht, Sandra, Yosifov, Deyan Yordanov, Mertens, Daniel, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Da Cunha-Bang, Caspar, Poulsen, Christian Bjorn, Illmer, Thomas, Schoettker, Bjoern, Janssens, Ann, Christiansen, Ilse, Noesslinger, Thomas, Baumann, Michael, Wendtner, Clemens-Martin, Eldering, Eric, Kreuzer, Karl-Anton, Ritgen, Matthias, Fink, Anna-Maria, Fischer, Kirsten, Kater, Arnon P., Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Tausch, Eugen, Schneider, Christof, Robrecht, Sandra, Zhang, Can, Dolnik, Anna, Bloehdorn, Johannes, Bahlo, Jasmin, Al-Sawaf, Othman, Ritgen, Matthias, Fink, Anna-Maria, Eichhorst, Barbara, Kreuzer, Karl-Anton, Tandon, Maneesh, Humphrey, Kathryn, Jiang, Yanwen, Schary, William, Bullinger, Lars, Mertens, Daniel, Lura, Michele Porro, Kneba, Michael, Doehner, Hartmut, Fischer, Kirsten, Hallek, Michael and Stilgenbauer, Stephan (2020). Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood, 135 (26). S. 2402 - 2413. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

von Tresckow, Julia, Cramer, Paula, Bahlo, Jasmin, Robrecht, Sandra, Engelke, Anja, Langerbeins, Petra, Fink, Anna-Maria, Illmer, Thomas, Klaproth, Holger, Estenfelder, Sven, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Bottcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2016). CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

von Tresckow, Julia, Cramer, Paula, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Illmer, Thomas, Klaproth, Holger, Estenfelder, Sven, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara F. and Hallek, Michael (2019). CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia, 33 (5). S. 1161 - 1173. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

von Tresckow, Julia ORCID: 0000-0001-5873-4603, Cramer, Paula ORCID: 0000-0003-4046-9922, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Fuerstenau, Moritz, Illmer, Thomas, Klaproth, Holger, Tausch, Eugen, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara F. and Hallek, Michael ORCID: 0000-0002-7425-4455 (2022). Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. Leukemia, 36 (8). S. 2125 - 2129. LONDON: SPRINGERNATURE. ISSN 1476-5551